In order to exploit XIAP as a putative pancreatic cancer target most efficiently, delivery of its antagonist, the SMAC peptidomimetic, needs to be rendered cancer selective, since a non-selective mimetic would increase the risks for systemic toxicities. Here, XIAP is linked to cancer.